HERO System - Health Monitoring for the Detection of Vital Signs and Emotional States
HERO
Observational Pilot Study on the Use of the HERO Health Monitoring System for the Detection of Vital Signs, Emotional States, and Body Postures
1 other identifier
observational
100
1 country
1
Brief Summary
New technologies offer significant opportunities to enhance the quality and intensity of care services, amplifying the ability to respond to patient needs through contactless solutions that also contribute to the humanization of care. Their application in patient monitoring can enable continuous observation, even in the absence of physically present staff, for a larger number of non-critical patients (thus reducing the risk of adverse events), and facilitate timely interventions when needed-aligned with the logic of Anglo-Saxon models based on Early Warning Systems. The general objective of this study is to conduct a pilot clinical trial of a specific solution based on Artificial Intelligence and Computer Vision, the HERO Health Monitoring (HHM) system, capable of detecting vital signs (heart rate, respiratory rate, blood oxygen saturation, and blood pressure), body posture, movements, and patients' emotional states-such as expressions of pain-using simple video devices. The study aims, in particular, to measure the concordance of the system's vital sign measurements with standard (telemetric) systems, and to assess the added value of combining these measurements with the additional information provided by HHM regarding posture, movement, and emotional state analysis-once their agreement has been verified against patient-reported outcomes collected via self-assessment questionnaires. This is an observational study involving the HERO Health Monitoring medical device, for which the certification process is expected to be completed through the present study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2025
CompletedFirst Submitted
Initial submission to the registry
August 10, 2025
CompletedFirst Posted
Study publicly available on registry
November 25, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedNovember 25, 2025
November 1, 2025
1.3 years
August 10, 2025
November 21, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Level of agreement between heart rate (measured as beats per minute) collected via HHM (Home Health Monitoring) system and those obtained from standard telemetry monitoring, measured using Intraclass Correlation Coefficient
This measure evaluates the level of concordance between heart rate (measured as beats per minute) collected by the HHM (Home Health Monitoring) system and those obtained from standard clinical telemetric monitoring systems. The agreement will be assessed using statistical methods such as Bland-Altman analysis, Intraclass Correlation Coefficient (ICC), and/or paired t-tests depending on the distribution and type of data. Measurements will be reported as mean values with standard deviations, and limits of agreement where appropriate.
6 months
Study Arms (1)
Patients hospitalized in the facilities of the Department of Cardiovascular Sciences
Eligibility Criteria
Patients hospitalized in the facilities of the Department of Cardiovascular Sciences will be consecutively enrolled in the pilot study, upon obtaining informed consent. Specifically, enrollment will include patients admitted to the 10 rooms equipped with the HERO monitoring device, starting from the first day of the study and continuing throughout its entire duration.
You may qualify if:
- Age over 18 years
- Signed informed consent
You may not qualify if:
- Age under 18 years
- Ongoing pregnancy
- Refusal to sign informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Giovanni Tinelli
Roma, Roma, 00136, Italy
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head Endovascular Unit at Fondazione Policlinico Gemelli IRCCS in Rome; Associate Professor of Vascular Surgery at Università Cattolica del Sacro Cuore in Rome, Italy
Study Record Dates
First Submitted
August 10, 2025
First Posted
November 25, 2025
Study Start
April 1, 2024
Primary Completion
August 1, 2025
Study Completion
December 31, 2025
Last Updated
November 25, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share